Company Overview

Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies for neurological, neuropsychiatric, immunologic, and rare diseases. The company operates within the biotechnology and pharmaceutical industries, with a primary emphasis on treatments targeting central nervous system disorders and immune-mediated conditions. Its core revenue and valuation drivers are tied to its late-stage and pipeline therapeutic candidates, strategic licensing arrangements, and intellectual property portfolio. Biohaven is particularly recognized for its work in calcitonin gene-related peptide (CGRP) therapeutics and glutamate modulation technologies.

The company traces its origins to Biohaven Pharmaceutical Holding Company Ltd., founded in 2013 by Dr. Vlad Coric and other biotechnology executives and researchers. In 2022, Pfizer Inc. acquired Biohaven’s commercial-stage CGRP migraine business, including approved migraine assets, while the remaining development-stage businesses continued as Biohaven Ltd., which now trades on the New York Stock Exchange under the ticker BHVN. Following the transaction, the company repositioned itself as a pipeline-focused biotechnology company with multiple investigational programs spanning neuroscience, immunology, oncology-supportive care, and rare disorders.

Business Operations

Biohaven organizes its operations primarily around proprietary drug development platforms and therapeutic programs rather than diversified commercial divisions. Key operational areas include the company’s glutamate modulation platform, myostatin inhibition programs, extracellular protein degradation technologies, and ion-channel targeting therapies. Major investigational assets include troriluzole for spinocerebellar ataxia and obsessive-compulsive disorder, taldefgrobep alfa for neuromuscular and metabolic disorders, and multiple antibody-based and small-molecule programs. The company generates revenue primarily through collaboration agreements, milestone payments, licensing activities, and investment financing, as it remains largely pre-commercial following the Pfizer transaction.

Biohaven maintains operations in the United States while advancing clinical programs globally through research institutions, contract research organizations, manufacturing partners, and academic collaborations. The company controls a broad intellectual property portfolio related to glutamatergic modulation, protein degradation, and neurotherapeutics. Strategic relationships have included collaborations and licensing arrangements with organizations such as Pfizer Inc., while the company also oversees subsidiaries and affiliated development entities supporting research, intellectual property management, and clinical operations.

Strategic Position & Investments

Biohaven’s strategic direction centers on developing high-value therapies for diseases with limited treatment options, particularly in neurology and immunology. The company has emphasized advancing multiple late-stage clinical programs simultaneously while leveraging platform technologies that may produce several therapeutic candidates across disease categories. Its strategy also includes maintaining a capital-light commercial structure during development phases and selectively partnering assets where external commercialization expertise or scale may provide advantages.

Following the 2022 asset sale to Pfizer Inc., Biohaven retained and expanded a diversified pipeline that includes extracellular protein degradation technologies, TRPM3 ion channel modulation, and antibody therapeutics. The company has invested significantly in clinical-stage neuroscience assets and rare disease programs, while also pursuing acquisitions and licensing opportunities to broaden its technology base. Biohaven’s positioning in neurotherapeutics is strengthened by management’s prior experience in migraine drug commercialization and by continuity of scientific leadership following the Pfizer transaction.

Geographic Footprint

Biohaven is headquartered in New Haven, Connecticut, with operational and research activities concentrated primarily in the United States. The company conducts multicenter clinical trials across North America, Europe, and selected international markets through partnerships with hospitals, academic centers, and contract research organizations. Its development activities are designed to support potential regulatory submissions in major pharmaceutical markets including the United States and the European Union.

The company’s international presence is driven mainly by global clinical development and intellectual property activities rather than large-scale commercial infrastructure. Through collaborations and outsourced manufacturing arrangements, Biohaven maintains operational relationships across multiple regions, including Europe and parts of Asia-Pacific. Its strategic influence internationally is tied to the global applicability of its therapeutic pipeline and prior commercialization experience associated with migraine therapies developed before the Pfizer acquisition.

Leadership & Governance

Biohaven was founded by Dr. Vlad Coric, who continues to play a central role in the company’s leadership and strategic direction. The company’s governance approach emphasizes scientific innovation, clinical execution, and long-term value creation through differentiated neurological and immunological therapies. Management has consistently highlighted accelerated development timelines, platform diversification, and disciplined capital allocation as key elements of corporate strategy.

Key executives include:

• Dr. Vlad Coric – Chairman and Chief Executive Officer
• Brian Garofolo – Chief Financial Officer
• Dr. Robert Berman – Chief Medical Officer
• Dr. Ivan Cheung – Director and strategic advisor with pharmaceutical commercialization experience
• Dr. Madhu Chugani – Senior clinical and development leadership roles in neuroscience programs

Leadership strategy has focused on leveraging expertise from prior successful CNS drug development efforts, particularly in migraine therapeutics, while building a broader multi-asset biotechnology platform targeting unmet medical needs.